Talazoparib (Talzenna)
Jump to navigation
Jump to search
Mechanism of action
PARP inhibitor
Diseases for which it is used
History of changes in FDA indication
- 10/16/2018: Initial approval for patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative locally advanced or metastatic breast cancer. (Based on EMBRACA)
Also known as
- Code name: BMN-673
- Brand name: Talzenna